Filing Analysis
🚪 Officer Departure
Filed Jun 10, 2026
⚪ LOW
Metagenomi Therapeutics reported the resignation of board member Brian C. Thomas, Ph.D., and the results of its 2026 annual meeting of stockholders. The meeting resulted in the election of two Class II directors and the ratification of PricewaterhouseCoopers LLP as the independent auditor.
🚩 Red Flags
- Multiple 8-K items (5.02 and 5.07) in a single filing, though both are routine administrative matters.
📋 Key Facts
- Brian C. Thomas, Ph.D. resigned from the Board of Directors effective June 9, 2026.
- The Company held its 2026 annual meeting on June 9, 2026, with a quorum of 19,116,207 shares present out of 37,647,057 outstanding.
- Juergen Eckhardt, M.D., M.B.A. and Eric Bjerkholt, M.B.A. were elected as Class II Directors to serve until 2029.
- PricewaterhouseCoopers LLP was ratified as the independent registered public accounting firm for the fiscal year ending December 31, 2026.
📢 Regulation FD Disclosure
Filed May 11, 2026
⚪ LOW
Metagenomi Therapeutics reported its financial results for the first quarter ended March 31, 2026, and provided a general business update. The filing also included an updated corporate presentation for May 2026.
📋 Key Facts
- Announced financial results for the quarter ended March 31, 2026.
- Furnished Exhibit 99.1 (Earnings Press Release) and Exhibit 99.2 (Corporate Presentation).
- The report was signed by CEO Jian Irish on May 11, 2026.
📢 Regulation FD Disclosure
Filed Mar 05, 2026
⚪ LOW
Metagenomi Therapeutics, Inc. (MGX) furnished its financial results for the fiscal year ended December 31, 2025, and provided general business updates. The disclosure was made via a press release furnished as an exhibit to the 8-K filing.
📋 Key Facts
- Announcement date: March 5, 2026
- Reporting period: Fiscal year ended December 31, 2025
- Filing includes Item 2.02 (Results of Operations and Financial Condition) and Item 9.01 (Exhibits)
- The company is classified as an emerging growth company
- The report was signed by President and CEO Jian Irish, Ph.D., M.B.A.
Disclaimer: This analysis is generated by AI and is for informational purposes only.
It does not constitute financial advice, investment recommendations, or an offer to buy or sell securities.
Always review the original SEC filings and consult a financial advisor before making investment decisions.